SM17, a new IL-17RB-targeting antibody, ameliorates disease progression in a mouse model of atopic dermatitis

Allergy. 2024 Jun;79(6):1625-1628. doi: 10.1111/all.16120. Epub 2024 Apr 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal* / pharmacology
  • Antibodies, Monoclonal* / therapeutic use
  • Dermatitis, Atopic* / drug therapy
  • Dermatitis, Atopic* / immunology
  • Disease Models, Animal
  • Disease Progression*
  • Humans
  • Mice
  • Receptors, Interleukin-17* / antagonists & inhibitors
  • Receptors, Interleukin-17* / immunology

Substances

  • Antibodies, Monoclonal
  • Receptors, Interleukin-17

Grants and funding